Cancer immunotherapy aims to leverage and amplify the natural capabilities of the immune system to combat cancer. The destruction of cancer cells can involve elements from both innate and adaptive immune responses. These include natural killer (NK) cells, cytotoxic T cells that depend on MHC recognition, antibody-producing B lymphocytes, engineered antibody formats like bispecific antibodies and bispecific T cell engagers (BiTEs), as well as genetically modified T cells designed to target specific tumor antigens, such as MHC-independent CAR-T cells.